title: High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
abstract: BACKGROUND
  Human immunodeficiency virus (HIV) infection is associated with a high risk of classical Hodgkin's lymphoma (cHL) in the combined antiretroviral therapy (cART) era.
  
  
  METHODS
  We analyzed the characteristics and outcome of HIV-associated cHL diagnosed in the modern cART era. The French ANRS-CO16 Lymphovir cohort enrolled 159 HIV-positive patients with lymphoma, including 68 (43%) with cHL. HIV-HL patients were compared with a series of non-HV-infected patients consecutively diagnosed with HL.
  
  
  RESULTS
  Most patients (76%) had Ann-Arbor stages III-IV and 96% of patients were treated with ABVD. At diagnosis, median CD4 T-cell count was 387/µL and 94% of patients were treated with cART. All patients received cART after diagnosis. Five patients died from early progression (n = 2), sepsis (1) or after relapse (2). Two additional patients relapsed during follow-up. Two-year overall and progression free survivals (PFS) were 94% [95% CI, 89%, 100%] and 89% [82%, 97%], respectively. The only factor associated with progression or death was age with a relative risk of 8.1 [1.0; 67.0] above 45 years. The PFS of Lymphovir patients appeared similar to PFS of HIV-negative patients, 86% [82%, 90%], but patients with HIV infection displayed higher risk features than HIV-negative patients.
  
  
  CONCLUSIONS
  Although high-risk features still predominate in HIV-HL, the prognosis of these patients, treated with cART and mainly ABVD, has markedly improved in the modern cART era and is now similar to non-HIV-infected patients.
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre AP-HP, Hôpitaux Paris Sud, Service d'hématologie, Le Kremlin-Bicêtre.
authors.forename: Caroline
authors.initials: C
authors.lastname: Besson
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06 INSERM, UMR_S 1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris.
authors.forename: Remi
authors.initials: R
authors.lastname: Lancar
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre AP-HP, Hôpitaux Paris Sud Site Béclère, Service d'anatomo-pathologie, Clamart.
authors.forename: Sophie
authors.initials: S
authors.lastname: Prevot
authors.affiliation: Department of Hemato-oncology, Hôpital Saint-Louis, AP-HP.
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.affiliation: AP-HP CHU Saint-Antoine, Service de maladies infectieuses, Paris.
authors.forename: Marie-Caroline
authors.initials: MC
authors.lastname: Meyohas
authors.affiliation: CHU Toulouse, Service de maladies infectieuses.
authors.forename: Bruno
authors.initials: B
authors.lastname: Marchou
authors.affiliation: AP-HP, CHU Pitié-Salpétrière, Service d'hématologie, Paris.
authors.forename: Jean
authors.initials: J
authors.lastname: Gabarre
authors.affiliation: CHU Bordeaux, Service de Médecine Interne et Maladies Infectieuses, and INSERM U593, Université de Bordeaux.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bonnet
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre AP-HP, Hôpitaux Paris Sud, Service d'hématologie, Le Kremlin-Bicêtre.
authors.forename: Cécile
authors.initials: C
authors.lastname: Goujard
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre AP-HP, Hôpitaux Paris Sud, Service d'hématologie, Le Kremlin-Bicêtre.
authors.forename: Olivier
authors.initials: O
authors.lastname: Lambotte
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre AP-HP, Hôpitaux Paris Sud Site Béclère, Service d'immunologie clinique, Clamart.
authors.forename: François
authors.initials: F
authors.lastname: Boué
authors.affiliation: Department of Onco-Hematology, Archet Hospital, Nice.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.affiliation: Hôpitaux Universitaires, Centre de soins de l'infection VIH, Strasbourg.
authors.forename: Marialuisa
authors.initials: M
authors.lastname: Partisani
authors.affiliation: CMIT, Paris.
authors.forename: Francois
authors.initials: F
authors.lastname: Raffi
authors.affiliation: Department of Hematology, Hôpital La Conception, Marseille.
authors.forename: Régis
authors.initials: R
authors.lastname: Costello
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre.
authors.forename: Houria
authors.initials: H
authors.lastname: Hendel-Chavez
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06 INSERM, UMR_S 1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris.
authors.forename: Michele
authors.initials: M
authors.lastname: Algarte-Genin
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06 INSERM, UMR_S 1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris.
authors.forename: Selma
authors.initials: S
authors.lastname: Trabelsi
authors.affiliation: ANRS, Paris.
authors.forename: Lucie
authors.initials: L
authors.lastname: Marchand
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre.
authors.forename: Martine
authors.initials: M
authors.lastname: Raphael
authors.affiliation: Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre AP-HP, Hôpitaux Paris Sud, Service d'imunologie biologique, Le Kremlin-Bicêtre, France.
authors.forename: Yassine
authors.initials: Y
authors.lastname: Taoufik
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06 INSERM, UMR_S 1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris.
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
mesh_terms: D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D001761:Bleomycin / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005602:France; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents; D000970:Antineoplastic Agents; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin
keywords: HIV; Hodgkin lymphoma; prognostic